An emerging leader in the immunotherapy space, we are advancing a pre-clinical pipeline of therapeutic candidates intended to elicit broad and durable anti-tumor and anti-viral responses and cure disease.
SEC Filings
U.S. Securities and Exchange Commission filings
View SEC Filings
Investor Contact
Will O’Conner
Stern Investor Relations
will.oconnor@sternir.com
Indaptus Management
Indaptus Board of Directors
Press Releases
Corporate Governance
Events and Presentations
March 28 – 30, 2022
2022 Virtual Growth Conference | Webcast Link
March 14 – 15, 2022
34th Annual ROTH Conference | Webcast Link
January 10, 2022 at 7AM ET
H.C. Wainwright BioConnect 2022 Virtual Conference | Webcast Link
Documents
March 2022
© 2021. Indaptus Therapeutics. All Rights Reserved. |